Olema Oncology, Inc.
OLMA Nasdaq
SEC CIK 1750284
Follow Olema Oncology
Weekly email: filings, results
Net income
−$73.6M
−74.3% vs same quarter last year
EPS, diluted
−$0.73
−49% vs same quarter last year
Operating cash flow
−$47.1M
−36.4% vs same quarter last year
Operating income
−$77.5M
−69% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$162.5M |
| FY24 | −$129.5M |
| FY23 | −$96.7M |
| FY22 | −$104.8M |
| FY21 | −$71.1M |
| FY20 | −$22.1M |
| FY19 | −$4.3M |
| FY18 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | −$104.5M |
| FY23 | - |
| FY22 | −$82.4M |
| FY21 | −$52.3M |
| FY20 | −$19.9M |
| FY19 | - |
| FY18 | - |